Facebook for Business | Cavern Retail Consulting

Posted on June 20, 2012 by Cathy

I teach workshops on Social Media in White Rock,BC.

Facebook has been in the news lately?for all the wrong reasons. First there was the IPO, and the disappointing stock prices. Then there was Mark Zuckerberg?s honeymoon in Europe?complete with his bad tipping at a spaghetti joint in Rome! If you have a business, these media tidbits probably don?t concern you. What you want to know, is how does the new Facebook Timeline affect how I share information with, and engage with my customers?

Facebook Timeline

If you created a Facebook page for your business ages ago, and have been pondering what to do with it?now might be the time to jump in and start creating content. Why? because the new Timeline feature really makes it easy to make that content stand out.

3 Facebook Timeline Marketing Tips for Success

I read this article yesterday, and loved the brevity of it. It also gave me simple instructions on the ?how-to?. I changed a few things on my own Facebook page(Cavern Retail Consulting- great small business/social media content. Hope you ?like? it.) immediately. No fuss?No Muss. I know you can do it too.

Even if you make just one change today?It?s a reason to tell your customers about your business, and strengthen your brand.

If you have any trouble,or questions?please contact me here?or if you live in the Surrey/White Rock area, sign up for one of my Facebook Workshops?The next one is July 3rd.

This entry was posted in Education, Marketing, Social Media and tagged facebook, Marketing, timeline. Bookmark the permalink. ? Times Change?Do You? |

la galaxy jordy nelson hot chelle rae guile alton brown weather los angeles caleb hanie

New drugs, new ways to target androgens in prostate cancer therapy

Public release date: 20-Jun-2012
[ | E-mail | Share ]

Contact: Erika Matich
erika.matich@ucdenver.edu
303-524-2780
University of Colorado Denver

AURORA, Colo. (June 20, 2012) - Prostate cancer cells require androgens including testosterone to grow. A recent review in the British Journal of Urology International describes new classes of drugs that target androgens in novel ways, providing alternatives to the traditional methods that frequently carry high side effects.

"In many ways, therapies for prostate cancer have led the way in the fight against the disease," says E. David Crawford, MD, investigator at the University of Colorado Cancer Center and review co-author. "The first effective oral therapy for any cancer was estrogen which was described in 1941. The first cancer biomarker that allowed diagnosis and staging was prostatic acid phosphatase back in 1938. Then there was little progress for over four decades."

During those 40 years, in which early work in prostate cancer led to Nobel prizes for researchers Charles Huggins and Andrew Schally, other cancer types capitalized on this research, notably developing hormone therapies targeting estrogen in breast cancer. But work in prostate cancer stalled.

"What we realized is that production of androgens like testosterone depends on an intact system in which the brain recognizes hormone levels, signals the pituitary to increase or decrease production, and the pituitary in turn sets the testes in motion. Additionally, by targeting the production of androgens by the testes, we could break that system at many other points," Crawford says.

For example, estrogen is similar enough to testosterone that administering estrogen to patients tricked the brain into thinking testosterone hormone levels were high with high presumed hormone levels, the brain sent no production signal to the pituitary. But estrogen therapy led to side effects including breast enlargement.

The next class of drugs, known as luteinizing hormone releasing hormones or LHRHs, intervened in this signaling chain at the level of the pituitary. Just as estrogen keeps the brain from signaling for more testosterone, LHRHs keep the pituitary from passing messages to the testes.

"Because the effects of LHRHs are reversible, this allowed us to use hormone-targeting therapies much earlier in the disease," Crawford says. "But LHRHs lead to an initial spike in testosterone, before it decreases." Most patients can withstand this spike, but for some, for example those with bone metastasis in the back, a spike in testosterone could flare the disease and lead to spinal complications.

"It was only about ten years ago that somebody was able to make a usable antagonist," Crawford says. Instead of first spiking and then lowering testosterone, these LHRH antagonists lead to an immediate drop.

And instead of targeting the signaling pathway that leads to the production of androgens including testosterone, androgen antagonists like Enzalutamide (formerly known as MDV3100), currently in phase III clinical trials, target cells' ability to trap testosterone that exists in the body it doesn't matter how much testosterone is floating around, as long as prostate cancer cells are unable to grab it. Specifically, Enzalutamide and other androgen antagonists are easier to "catch" than the androgens themselves, and so cells grab Enzalutamide and are then unable to grab testosterone.

Also new to the field are drugs that block the production of androgens from all sources which of course includes the testes, but also includes blocking the smaller amounts produced by the adrenals and even by the cancer itself. This class of drugs is called androgen biosynthesis inhibitors, and the first approved is a drug called abiraterone or Zytiga.

"Targeting cells' androgen receptors is a new and exciting development in the field of prostate cancer therapy," Crawford says. "As these new drugs make their way from the lab to clinic, we expect the ability to offer androgen antagonists to patients whose cancers have resisted other treatments."

###

Dr. Crawford wishes to disclose that he is an advisor to the company Medivation, which manufactures the drug Enzolutamide.

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Public release date: 20-Jun-2012
[ | E-mail | Share ]

Contact: Erika Matich
erika.matich@ucdenver.edu
303-524-2780
University of Colorado Denver

AURORA, Colo. (June 20, 2012) - Prostate cancer cells require androgens including testosterone to grow. A recent review in the British Journal of Urology International describes new classes of drugs that target androgens in novel ways, providing alternatives to the traditional methods that frequently carry high side effects.

"In many ways, therapies for prostate cancer have led the way in the fight against the disease," says E. David Crawford, MD, investigator at the University of Colorado Cancer Center and review co-author. "The first effective oral therapy for any cancer was estrogen which was described in 1941. The first cancer biomarker that allowed diagnosis and staging was prostatic acid phosphatase back in 1938. Then there was little progress for over four decades."

During those 40 years, in which early work in prostate cancer led to Nobel prizes for researchers Charles Huggins and Andrew Schally, other cancer types capitalized on this research, notably developing hormone therapies targeting estrogen in breast cancer. But work in prostate cancer stalled.

"What we realized is that production of androgens like testosterone depends on an intact system in which the brain recognizes hormone levels, signals the pituitary to increase or decrease production, and the pituitary in turn sets the testes in motion. Additionally, by targeting the production of androgens by the testes, we could break that system at many other points," Crawford says.

For example, estrogen is similar enough to testosterone that administering estrogen to patients tricked the brain into thinking testosterone hormone levels were high with high presumed hormone levels, the brain sent no production signal to the pituitary. But estrogen therapy led to side effects including breast enlargement.

The next class of drugs, known as luteinizing hormone releasing hormones or LHRHs, intervened in this signaling chain at the level of the pituitary. Just as estrogen keeps the brain from signaling for more testosterone, LHRHs keep the pituitary from passing messages to the testes.

"Because the effects of LHRHs are reversible, this allowed us to use hormone-targeting therapies much earlier in the disease," Crawford says. "But LHRHs lead to an initial spike in testosterone, before it decreases." Most patients can withstand this spike, but for some, for example those with bone metastasis in the back, a spike in testosterone could flare the disease and lead to spinal complications.

"It was only about ten years ago that somebody was able to make a usable antagonist," Crawford says. Instead of first spiking and then lowering testosterone, these LHRH antagonists lead to an immediate drop.

And instead of targeting the signaling pathway that leads to the production of androgens including testosterone, androgen antagonists like Enzalutamide (formerly known as MDV3100), currently in phase III clinical trials, target cells' ability to trap testosterone that exists in the body it doesn't matter how much testosterone is floating around, as long as prostate cancer cells are unable to grab it. Specifically, Enzalutamide and other androgen antagonists are easier to "catch" than the androgens themselves, and so cells grab Enzalutamide and are then unable to grab testosterone.

Also new to the field are drugs that block the production of androgens from all sources which of course includes the testes, but also includes blocking the smaller amounts produced by the adrenals and even by the cancer itself. This class of drugs is called androgen biosynthesis inhibitors, and the first approved is a drug called abiraterone or Zytiga.

"Targeting cells' androgen receptors is a new and exciting development in the field of prostate cancer therapy," Crawford says. "As these new drugs make their way from the lab to clinic, we expect the ability to offer androgen antagonists to patients whose cancers have resisted other treatments."

###

Dr. Crawford wishes to disclose that he is an advisor to the company Medivation, which manufactures the drug Enzolutamide.

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

new orleans hornets ghost rider spirit of vengeance hornets prince johan friso windows 8 logo anguilla gone with the wind

Health Care Tips: How to Cure a Sore Throat

A sore throat is a frequent condition among many people and is often the result of a common cold or flu virus. Having this ailment is usually inconvenient. You may feel irritation on your tonsils, which can cause soreness. While the ideal way to avoid having a sore throat is keeping away from those infected with the common cold or flu virus, it might not always be possible. Fortunately, you can use several sore throat home remedies. Adopt these measures to relieve irritation and soreness.

Consume fluids

Drinking eight glasses of water every day will help the body recover and hydrated if you have the flu. For example, drinking water can help decrease the amount of mucus secretions and relieve your tonsils. Try blending honey and lemon with hot water, since this also helps minimize mucus build-up.

Drinking herbal tea might also help soothe and relieve irritation. Avoid drinking fluids that contain caffeine since these will undoubtedly worsen your problem. ?

Gargle with salt-water solution

Mix together 8 ounces of hot water with 1/2 teaspoon of salt. Gargle the solution at least four times each day to relieve irritation. Gargling with salt-water solution is one of the several sore throat home remedies suggested by physicians. Inflammations, also referred to as edemas, are present if you are suffering from an aching throat. These inflammations have water and bacteria that causes sickness. The solution eliminates the edemas, draws out water, and eliminates the bacteria. The solution also lessens swelling, making it less difficult to swallow and speak. It also boosts blood flow in the affected areas, which boosts antibodies and rushes recovery.

Use oral sprays

Throat sprays are also excellent solutions. These contain substances like menthol and benzocaine that can minimize pain and act as local anesthetics. These also function as disinfectants because they get rid of bacteria causing inflammation and itchiness. They are available in convenient spray bottles you can bring everywhere you go. Use as often as needed or as recommended by your medical doctor - do not go beyond 20ml or eighty sprays each day. Natural oral sprays are also offered at local drug stores. These have menthol and natural substances such as bee propolis, elm extract, and clove oil. These also do not have any chemical preservatives or coloring. Consult your health care provider how to cure a sore throat using these oral sprays.

Start using humidifiers or vaporizers

Humidifiers and vaporizers can increase the moisture inside your space. These prevent the surroundings from becoming dry and enhance air flow inside your home. Humidifiers and vaporizers are recommended if you go to sleep with your mouth open. These might also help you stay comfy while recovering from a cold or flu virus.

Take over-the-counter medicines

Medicines like Tylenol and ibuprofen might help minimize irritation and pain as a result of a sore throat. Consume these medicines in four-hour periods to lessen irritation immediately. Several physicians might also recommend lozenges. Antibiotics are also necessary to get rid of bacteria causing the soreness. Talk to your physician how to cure a sore throat using these medicines to avoid worsening your condition.

Visit a medical doctor

Consult your physician if your sore throat goes on for more than a week, particularly if your temperature is higher than 38 degree Celsius. Consult your doctor prior to using any remedies. Learn more about different sore throat home remedies from your doctor.

heather locklear hospitalized joplin tornado extreme makeover home edition constitution day constitution day coachella 2012 dolly parton

e-Therapeutics cancer drug enters US phase I trials ...

Wed 3:38 am by Natasha Barr

?

Drug discovery and development company e-Therapeutics () is to start a US phase I clinical trial for its brain cancer drug ETS2101.

The trial is one of two studies scheduled for the drug, with a larger, UK-based trial studying the drug in patients with a variety of tumour types also starting shortly.

The US phase I trial is enrolling up to 24 brain cancer patients with primary brain cancer, called glioma, or cancer that has spread to the brain from other sites. First findings are expected in late 2012.

ETS2101 works by overcoming cancer cells? ability to evade apoptosis, which is the mechanism where cells normally self-destruct if they become dysfunctional.

It said it decided to also run a brain cancer trial because ETS2101 has shown it can cross between the circulating blood and the central nervous system fluid in the brain, unlike many current cancer drugs.

The primary objective of the trial is to evaluate safety and to determine an appropriate dose for phase II studies.

Development director, Steve Self, said: ?Advancing ETS2101 into trials was one of our key goals following last year?s refinancing and refocusing of our business.We look forward with interest to seeing the first results from the clinic.?

e-Therapeutics currently has three clinical candidates, spanning cancer, infectious diseases, such as hospital infection bug and MRSA, and psychiatric disorders.

e-Therapeutics uses its network pharmacology platform for drug discovery, which looks at all the effects a molecule might have on all the networks in the cell, unlike other methods which just target single proteins.

?

?

to catch a predator davenport chris hansen ehlers danlos syndrome the closer michael turner split pea soup

Confusion can be beneficial for learning

ScienceDaily (June 20, 2012) ? Most of us assume that confidence and certainty are preferred over uncertainty and bewilderment when it comes to learning complex information. But a new study led by Sidney D'Mello of the University of Notre Dame shows that confusion when learning can be beneficial if it is properly induced, effectively regulated and ultimately resolved.

The study will be published in a forthcoming issue of the journal Learning and Instruction.

Notre Dame psychologist and computer scientist D'Mello, whose research areas include artificial intelligence, human-computer interaction and the learning sciences, together with Art Graesser of the University of Memphis, collaborated on the study, which was funded by the National Science Foundation.

They found that by strategically inducing confusion in a learning session on difficult conceptual topics, people actually learned more effectively and were able to apply their knowledge to new problems.

In a series of experiments, subjects learned scientific reasoning concepts through interactions with computer-animated agents playing the roles of a tutor and a peer learner. The animated agents and the subject engaged in interactive conversations where they collaboratively discussed the merits of sample research studies that were flawed in one critical aspect. For example, one hypothetical case study touted the merits of a diet pill, but was flawed because it did not include an appropriate control group. Confusion was induced by manipulating the information the subjects received so that the animated agents sometimes disagreed with each other and expressed contradictory or incorrect information. The agents then asked subjects to decide which opinion had more scientific merit, thereby putting the subject in the hot spot of having to make a decision with incomplete and sometimes contradictory information.

In addition to the confusion and uncertainty triggered by the contradictions, subjects who were confused scored higher on a difficult post-test and could more successfully identify flaws in new case studies.

"We have been investigating links between emotions and learning for almost a decade, and find that confusion can be beneficial to learning if appropriately regulated because it can cause learners to process the material more deeply in order to resolve their confusion," D'Mello says.

According to D'Mello, it is not advisable to intentionally confuse students who are struggling or induce confusion during high-stakes learning activities. Confusion interventions are best for higher-level learners who want to be challenged with difficult tasks, are willing to risk failure, and who manage negative emotions when they occur.

"It is also important that the students are productively instead of hopelessly confused. By productive confusion, we mean that the source of the confusion is closely linked to the content of the learning session, the student attempts to resolve their confusion, and the learning environment provides help when the student struggles. Furthermore, any misleading information in the form of confusion-induction techniques should be corrected over the course of the learning session, as was done in the present experiments."

According to D'Mello, the next step in this body of research is to apply these methods to some of the more traditional domains such as physics, where misconceptions are common.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

---

Story Source:

The above story is reprinted from materials provided by University of Notre Dame.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

---

Journal Reference:

1. Sidney D?Mello, Blair Lehman, Reinhard Pekrun, Art Graesser. Confusion can be beneficial for learning. Learning and Instruction, 2012; DOI: 10.1016/j.learninstruc.2012.05.003

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

the secret world of arrietty cee lo allen iverson jr smith chris anderson rondo suspended bay bridge

Video: P&G Shares Drop on Lower Earnings Guidance

Sorry, Readability was unable to parse this page for content.

serrano ground hog donald trump staten island chuck dr jekyll and mr hyde edwin jackson punksatony phil

Nalbandian fined $12K and faces assault inquiry

[ [ [['Connery is an experienced stuntman', 2]], 'http://yhoo.it/KeQd0p', '[Slideshow: See photos taken on the way down]', ' ', '630', ' ', ' ', ], [ [['Connery is an experienced stuntman', 7]], ' http://yhoo.it/KpUoHO', '[Slideshow: Death-defying daredevils]', ' ', '630', ' ', ' ', ], [ [['know that we have confidence in', 3]], 'http://yhoo.it/LqYjAX ', '[Related: The Secret Service guide to Cartagena]', ' ', '630', ' ', ' ', ], [ [['We picked up this other dog and', 5]], 'http://yhoo.it/JUSxvi', '[Related: 8 common dog fears, how to calm them]', ' ', '630', ' ', ' ', ], [ [['accused of running a fake hepatitis B', 5]], 'http://bit.ly/JnoJYN', '[Related: Did WH share raid details with filmmakers?]', ' ', '630', ' ', ' ', ], [ [['accused of running a fake hepatitis B', 3]], 'http://bit.ly/KoKiqJ', '[Factbox: AQAP, al-Qaeda in Yemen]', ' ', '630', ' ', ' ', ], [ [['have my contacts on or glasses', 3]], 'http://abcn.ws/KTE5AZ', '[Related: Should the murder charge be dropped?]', ' ', '630', ' ', ' ', ], [ [['have made this nation great as Sarah Palin', 5]], 'http://yhoo.it/JD7nlD', '[Related: Bristol Palin reality show debuts June 19]', ' ', '630', ' ', ' ', ], [ [['have made this nation great as Sarah Palin', 1]], 'http://bit.ly/JRPFRO', '[Related: McCain adviser who vetted Palin weighs in on VP race]', ' ', '630', ' ', ' ', ], [ [['A JetBlue flight from New York to Las Vegas', 3]], 'http://yhoo.it/GV9zpj', '[Related: View photos of the JetBlue plane in Amarillo]', ' ', '630', ' ', ' ', ], [ [['the 28-year-old neighborhood watchman who shot and killed', 15]], 'http://news.yahoo.com/photos/white-house-stays-out-of-teen-s-killing-slideshow/', 'Click image to see more photos', 'http://l.yimg.com/cv/ip/ap/default/120411/martinzimmermen.jpg', '630', ' ', 'AP', ], [ [['Titanic', 7]], 'http://news.yahoo.com/titanic-anniversary/', ' ', 'http://l.yimg.com/a/p/us/news/editorial/b/4e/b4e5ad9f00b5dfeeec2226d53e173569.jpeg', '550', ' ', ' ', ], [ [['He was in shock and still strapped to his seat', 6]], 'http://news.yahoo.com/photos/navy-jet-crashes-in-virginia-slideshow/', 'Click image to see more photos', 'http://l.yimg.com/cv/ip/ap/default/120406/jet_ap.jpg', '630', ' ', 'AP', ], [ [['xxxxxxxxxxxx', 11]], 'http://news.yahoo.com/photos/russian-grannies-win-bid-to-sing-at-eurovision-1331223625-slideshow/', 'Click image to see more photos', 'http://l.yimg.com/a/p/us/news/editorial/1/56/156d92f2760dcd3e75bcd649a8b85fcf.jpeg', '500', ' ', 'AP', ] ]

[ [ [['did not go as far his colleague', 8]], '29438204', '0' ], [ [[' the 28-year-old neighborhood watchman who shot and killed', 4]], '28924649', '0' ], [ [['because I know God protects me', 14], ['Brian Snow was at a nearby credit union', 5]], '28811216', '0' ], [ [['The state news agency RIA-Novosti quoted Rosaviatsiya', 6]], '28805461', '0' ], [ [['measure all but certain to fail in the face of bipartisan', 4]], '28771014', '0' ], [ [['matter what you do in this case', 5]], '28759848', '0' ], [ [['presume laws are constitutional', 7]], '28747556', '0' ], [ [['has destroyed 15 to 25 houses', 7]], '28744868', '0' ], [ [['short answer is yes', 7]], '28746030', '0' ], [ [['opportunity to tell the real story', 7]], '28731764', '0' ], [ [['entirely respectable way to put off the searing constitutional controversy', 7]], '28723797', '0' ], [ [['point of my campaign is that big ideas matter', 9]], '28712293', '0' ], [ [['As the standoff dragged into a second day', 7]], '28687424', '0' ], [ [['French police stepped up the search', 17]], '28667224', '0' ], [ [['Seeking to elevate his candidacy back to a general', 8]], '28660934', '0' ], [ [['The tragic story of Trayvon Martin', 4]], '28647343', '0' ], [ [['Karzai will get a chance soon to express', 8]], '28630306', '0' ], [ [['powerful storms stretching', 8]], '28493546', '0' ], [ [['basic norm that death is private', 6]], '28413590', '0' ], [ [['songwriter also saw a surge in sales for her debut album', 6]], '28413590', '1', 'Watch music videos from Whitney Houston ', 'on Yahoo! Music', 'http://music.yahoo.com' ], [ [['keyword', 99999999999999999999999]], 'videoID', '1', 'overwrite-pre-description', 'overwrite-link-string', 'overwrite-link-url' ] ]

watergate mlb ufc pregnant man outside lands 2012 lineup beloved ufc results